Molecular Pain

[1]  B. Perkins,et al.  Neuropathy. , 2013, Canadian journal of diabetes.

[2]  D. Fink,et al.  The Role of TNFα in the Periaqueductal Gray During Naloxone-Precipitated Morphine Withdrawal in Rats , 2011, Neuropsychopharmacology.

[3]  R. Pang,et al.  TNF-α contributes to up-regulation of Nav1.3 and Nav1.8 in DRG neurons following motor fiber injury , 2010, PAIN®.

[4]  E. Dennis,et al.  Spinal glial TLR4‐mediated nociception and production of prostaglandin E2 and TNF , 2010, British journal of pharmacology.

[5]  Takahiko Horiuchi,et al.  Transmembrane TNF-α: structure, function and interaction with anti-TNF agents , 2010, Rheumatology.

[6]  M. Korostyński,et al.  Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. , 2009, European journal of pharmacology.

[7]  K. Williams,et al.  HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[8]  J. Glorioso,et al.  Effects of transgene‐mediated endomorphin‐2 in inflammatory pain , 2009, European journal of pain.

[9]  A. Gaspari,et al.  Inflammatory papillomatous hyperplasia and epidermal necrosis in a transgenic rat for HIV-1. , 2009, Journal of dermatological science.

[10]  W. Guo,et al.  Supraspinal Glial–Neuronal Interactions Contribute to Descending Pain Facilitation , 2008, The Journal of Neuroscience.

[11]  D. Fink,et al.  HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor α in spinal cord microglia , 2008, Gene Therapy.

[12]  J. Reveille,et al.  The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease , 2007, Annals of the rheumatic diseases.

[13]  Andrew S.C. Rice,et al.  Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy , 2007, PAIN®.

[14]  Johnny J. He,et al.  Protection against human immunodeficiency virus type 1 Tat neurotoxicity by Ginkgo biloba extract EGb 761 involving glial fibrillary acidic protein. , 2007, The American journal of pathology.

[15]  Andrew R Segerdahl,et al.  Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. , 2007, Brain : a journal of neurology.

[16]  J. Glorioso,et al.  Gene transfer to interfere with TNFα signaling in neuropathic pain , 2007, Gene Therapy.

[17]  R. Meeker.  Feline Immunodeficiency Virus Neuropathogenesis: From Cats to Calcium , 2007, Journal of Neuroimmune Pharmacology.

[18]  E. Masliah,et al.  NeuroAIDS, Drug Abuse, and Inflammation: Building Collaborative Research Activities , 2006, Journal of Neuroimmune Pharmacology.

[19]  B. Gelman,et al.  Abnormal Striatal Dopaminergic Synapses in National NeuroAIDS Tissue Consortium Subjects with HIV Encephalitis , 2006, Journal of Neuroimmune Pharmacology.

[20]  Ji-Tian Xu,et al.  The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat , 2006, PAIN.

[21]  D. Clifford,et al.  HIV neuropathy natural history cohort study , 2006, Neurology.

[22]  J. Glorioso,et al.  Tumor necrosis factor–α contributes to below‐level neuropathic pain after spinal cord injury , 2006 .

[23]  M. Roth,et al.  Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. , 2005, Life sciences.

[24]  Christine Fennema-Notestine,et al.  Effects of methamphetamine dependence and HIV infection on cerebral morphology. , 2005, The American journal of psychiatry.

[25]  S. McMahon,et al.  Role of the Immune system in chronic pain , 2005, Nature Reviews Neuroscience.

[26]  M. Kaul,et al.  HIV-1 infection and AIDS: consequences for the central nervous system , 2005, Cell Death and Differentiation.

[27]  A. Brooks,et al.  A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Johnny J. He,et al.  Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes , 2004, Molecular and Cellular Neuroscience.

[29]  V. Tawfik,et al.  Neuroimmune Activation and Neuroinflammation in Chronic Pain and Opioid Tolerance/Hyperalgesia , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[30]  S. Maier,et al.  GLIA: A novel drug discovery target for clinical pain , 2003, Nature Reviews Drug Discovery.

[31]  J. McArthur,et al.  Schwann cell chemokine receptors mediate HIV‐1 gp120 toxicity to sensory neurons , 2003, Annals of neurology.

[32]  S. Mahajan,et al.  Immunological assays for chemokine detection in in-vitro culture of CNS cells , 2003, Biological Procedures Online.

[33]  L. Sorkin,et al.  Tumor Necrosis Factor-α Induces Mechanical Allodynia after Spinal Nerve Ligation by Activation of p38 MAPK in Primary Sensory Neurons , 2003, The Journal of Neuroscience.

[34]  M. Antoni,et al.  HIV-1 Infection and its Impact on the HPA Axis, Cytokines, and Cognition , 2003, Stress.

[35]  J. Deleo,et al.  The Role of Spinal Neuroimmune Activation in Morphine Tolerance/Hyperalgesia in Neuropathic and Sham-Operated Rats , 2002, The Journal of Neuroscience.

[36]  C. Woolf,et al.  Can we conquer pain? , 2002, Nature Neuroscience.

[37]  K. Marder,et al.  Incidence of and risk factors for HIV-associated distal sensory polyneuropathy , 2002, Neurology.

[38]  S. Brull,et al.  A comparison of chronic pain behavior following local application of tumor necrosis factor α to the normal and mechanically compressed lumbar ganglia in the rat , 2002, Pain.

[39]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[40]  M. Reitz,et al.  An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R J Miller,et al.  Chemokines and Glycoprotein120 Produce Pain Hypersensitivity by Directly Exciting Primary Nociceptive Neurons , 2001, The Journal of Neuroscience.

[42]  J. Deleo,et al.  Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. , 2001, The Journal of pharmacology and experimental therapeutics.

[43]  J. Sagen,et al.  Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis , 2001, Journal of Neuroimmunology.

[44]  S. Maier,et al.  Intrathecal HIV-1 Envelope Glycoprotein gp120 Induces Enhanced Pain States Mediated by Spinal Cord Proinflammatory Cytokines , 2001, The Journal of Neuroscience.

[45]  J. Deleo,et al.  Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain , 2001, Neuroscience.

[46]  K. Conant,et al.  The role of chemokines in human immunodeficiency virus infection , 2000, Immunological reviews.

[47]  J. Weinstein,et al.  Spinal glial activation and cytokine expression after lumbar root injury in the rat. , 2000, Spine.

[48]  S. Maier,et al.  Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120 , 2000, Brain Research.

[49]  C. Sommer,et al.  Hyperalgesia in Experimental Neuropathy Is Dependent on the TNF Receptor 1 , 1998, Experimental Neurology.

[50]  C. Plata-salamán,et al.  HIV-1 Envelope Glycoprotein 120 Regulates Brain IL-1β System and TNF-α mRNAs In Vivo , 1997, Brain Research Bulletin.

[51]  G. Newshan,et al.  Pain in human immunodeficiency virus disease. , 1997, Seminars in oncology nursing.

[52]  S. Deeks,et al.  Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection , 1996, The Lancet.

[53]  D. Wallach,et al.  Inhibition of Tumor Necrosis Factor Alpha (TNFα) Activity in Rat Brain is Associated with Cerebroprotection after Closed Head Injury , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[54]  T. Yaksh,et al.  Quantitative assessment of tactile allodynia in the rat paw , 1994, Journal of Neuroscience Methods.

[55]  N. Liabakk,et al.  Serum Levels of Tumor Necrosis Factor-α (TNFα) and Soluble TNF Receptors in Human Immunodeficiency Virus Type 1 Infection-Correlations to Clinical, Immunologic, and Virologic Parameters , 1994 .

[56]  J. Glass,et al.  Cytokine expression in the brain during the acquired immunodeficiency syndrome , 1992, Annals of neurology.

[57]  J. Merrill,et al.  HIV‐1, macrophages, glial cells, and cytokines in AIDS nervous system disease , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[59]  S. Dorsey,et al.  HIV peripheral neuropathy: pathophysiology and clinical implications. , 2006, AACN clinical issues.

[60]  P. Tan,et al.  Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat , 2005, Gene Therapy.

[61]  L. Sorkin,et al.  Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[62]  C. Plata-salamán,et al.  HIV-1 envelope glycoprotein 120 regulates brain IL-1beta system and TNF-alpha mRNAs in vivo. , 1997, Brain research bulletin.

[63]  D. Wallach,et al.  Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[64]  N. Yamamoto.  The role of cytokines in the acquired immunodeficiency syndrome , 1995, International journal of clinical & laboratory research.

[65]  N. Liabakk,et al.  Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. , 1994, The Journal of infectious diseases.

[66]  S. Lipton,et al.  Neuronal injury associated with HIV-1 and potential treatment with calcium-channel and NMDA antagonists. , 1994, Developmental neuroscience.

[67]  L. Epstein,et al.  Human immunodeficiency virus type 1 (HIV-1) infection of the nervous system: a review. , 1988, Immunodeficiency reviews.

[68]  W. Dixon,et al.  Efficient analysis of experimental observations. , 1980, Annual review of pharmacology and toxicology.